Nektar Therapeutics Company Profile (NASDAQ:NKTR)

About Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics logoNektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its programs include Immuno-oncology (I-O), Immunology, Pain-NKTR-181 and Oncology-ONZEALD. It is developing medicines designed to directly or indirectly modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:NKTR
  • CUSIP: 64026810
  • Web: www.nektar.com
Capitalization:
  • Market Cap: $3.23 billion
  • Outstanding Shares: 155,149,000
Average Prices:
  • 50 Day Moving Avg: $19.10
  • 200 Day Moving Avg: $15.62
  • 52 Week Range: $11.41 - $24.88
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -20.58
  • P/E Growth: 2.43
Sales & Book Value:
  • Annual Revenue: $131.28 million
  • Price / Sales: 24.57
  • Book Value: $0.29 per share
  • Price / Book: 71.69
Profitability:
  • EBIDTA: ($142,140,000.00)
  • Net Margins: -98.87%
  • Return on Equity: -8,769.15%
  • Return on Assets: -35.17%
Debt:
  • Debt-to-Equity Ratio: -3.61%
  • Current Ratio: 3.70%
  • Quick Ratio: 3.56%
Misc:
  • Average Volume: 2.22 million shs.
  • Beta: 1.84
  • Short Ratio: 5.79
 

Frequently Asked Questions for Nektar Therapeutics (NASDAQ:NKTR)

What is Nektar Therapeutics' stock symbol?

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) announced its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.42) EPS for the quarter, missing the Zacks' consensus estimate of ($0.40) by $0.02. The firm earned $24.73 million during the quarter, compared to analyst estimates of $29.43 million. Nektar Therapeutics had a negative net margin of 98.87% and a negative return on equity of 8,769.15%. The company's revenue was down 58.0% on a year-over-year basis. During the same period last year, the business posted ($0.14) EPS. View Nektar Therapeutics' Earnings History.

What guidance has Nektar Therapeutics issued on next quarter's earnings?

Nektar Therapeutics updated its FY16 earnings guidance on Wednesday, March, 1st. The company provided earnings per share guidance of ($1.10) for the period, compared to the Thomson Reuters consensus EPS estimate of ($1.08). The company issued revenue guidance of $165.40 million, compared to the consensus revenue estimate of $168.12 million.

Where is Nektar Therapeutics' stock going? Where will Nektar Therapeutics' stock price be in 2017?

7 brokerages have issued 12-month target prices for Nektar Therapeutics' shares. Their predictions range from $23.00 to $31.00. On average, they expect Nektar Therapeutics' share price to reach $26.29 in the next twelve months. View Analyst Ratings for Nektar Therapeutics.

What are analysts saying about Nektar Therapeutics stock?

Here are some recent quotes from research analysts about Nektar Therapeutics stock:

  • 1. According to Zacks Investment Research, "Nektar reported wider than expected loss in fourth quarter 2016 with revenue missing estimates. The launches of its drugs Movantik and Adynovate have been on track with both the products performing impressively. Moreover, partnerships have enhanced the company’s financial position. Nektar stands to receive significant sales milestone plus royalties for Movantik under the license agreement with AstraZeneca, which will boost its financial position significantly. Nektar also has a deep and promising pipeline, with several updates lined up for the next several quarters. However, Nektar relies heavily on partners for revenues. Partnership-related setbacks may weigh heavily on the company, and disappointing products sales could have a significant impact on its financial results. The company’s shares outperformed the Zacks classified Medical-Drugs industry in the year so far." (3/27/2017)
  • 2. BTIG Research analysts commented, "Nektar announced positive results from the Phase 3 SUMMIT-07 study of NKTR-181, its novel, proprietary, abuse-resistant opioid for pain. NKTR- 181 met all important primary and secondary efficacy endpoints in the 610- patient study, and the molecule appeared well tolerated, materially derisking the program. At its primary endpoint at week 12 postrandomization, average pain scores increased 1.46 points on the Numeric Rating Scale with placebo, vs. 0.92 points for NKTR-181 (p=0.0019); other secondary endpoints were also as positive. NKTR-181 has been FastTracked, a rarity for an opioid, and with this highly positive study in hand, there is a possibility for rapid progression of NKTR-181, and a material partnership. With 181's success, and with the potential for additional meaningful catalysts near-term, we raise our NKTR price target to $27." (3/21/2017)
  • 3. Jefferies Group LLC analysts commented, "The unexpected Ph 3 success for '181 brings this once very promising mu-opioid analgesic asset back to life. In our view, it could become NKTR's largest and most profitable product as it squarely addresses the 'opioid epidemic'. Mgt hopes to partner the drug by YE. We believe '181 could bring significant value (modeling 30% royalties and $250M+ in milestones) to the company as early as 2020. With this asset now unencumbered, NKTR now fits our M&A thesis." (3/21/2017)
  • 4. Aegis analysts commented, "NKTR-181 met its primary endpoint in the phase III Summit-07 trial - increase Price Target to $25. Yesterday morning, Netkar Therapeutics announced that NKTR-181 met its primary endpoint of mean change in weekly average numeric rating scale (NRS) pain score for the randomized, double-blind treatment period from the end of the open-label titration period (baseline) to week 12. Average pain scores measured at week 12 from baseline increased 1.46 for placebo vs. 0.92 for NKTR-181 (p=0.0019). We had not previously factored in revenue from NKTR-181 into our price target. As a result of the positive phase III results, we now include such revenue under partnering assumptions in the US and raise our price target from $21 to $24." (3/20/2017)

Who are some of Nektar Therapeutics' key competitors?

Who owns Nektar Therapeutics stock?

Nektar Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include OppenheimerFunds Inc. (15.61%), Primecap Management Co. CA (13.95%), BlackRock Inc. (13.02%), Vanguard Group Inc. (8.85%), Camber Capital Management LLC (3.51%) and Westfield Capital Management Co. LP (2.62%). Company insiders that own Nektar Therapeutics stock include Christopher A Kuebler, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Maninder Hora, R Scott Greer, Robert Chess, Stephen K Doberstein and Susan Wang. View Institutional Ownership Trends for Nektar Therapeutics.

Who sold Nektar Therapeutics stock? Who is selling Nektar Therapeutics stock?

Nektar Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Granahan Investment Management Inc. MA, OppenheimerFunds Inc., Camber Capital Management LLC, Morgan Stanley, Credit Suisse AG, Westfield Capital Management Co. LP, State Street Corp and Candriam Luxembourg S.C.A.. Company insiders that have sold Nektar Therapeutics stock in the last year include Christopher A Kuebler, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Maninder Hora, Robert Chess and Stephen K Doberstein. View Insider Buying and Selling for Nektar Therapeutics.

Who bought Nektar Therapeutics stock? Who is buying Nektar Therapeutics stock?

Nektar Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Vanguard Group Inc., FMR LLC, Teachers Advisors LLC, Bank of New York Mellon Corp and First Trust Advisors LP. View Insider Buying and Selling for Nektar Therapeutics.

How do I buy Nektar Therapeutics stock?

Shares of Nektar Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Nektar Therapeutics stock cost?

One share of Nektar Therapeutics stock can currently be purchased for approximately $20.79.

Analyst Ratings

Consensus Ratings for Nektar Therapeutics (NASDAQ:NKTR) (?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $26.29 (26.43% upside)

Analysts' Ratings History for Nektar Therapeutics (NASDAQ:NKTR)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/22/2017Roth CapitalSet Price TargetBuy$31.00MediumView Rating Details
5/10/2017Jefferies Group LLCLower Price TargetBuy$25.00 -> $23.00MediumView Rating Details
5/10/2017AegisReiterated RatingBuy$27.00HighView Rating Details
4/11/2017Piper Jaffray CompaniesReiterated RatingOverweight$29.00LowView Rating Details
3/21/2017BTIG ResearchBoost Price TargetPositive$22.00 -> $27.00MediumView Rating Details
3/21/2017JPMorgan Chase & Co.Set Price TargetBuy$24.00MediumView Rating Details
9/30/2016Brean CapitalReiterated RatingBuy$23.00N/AView Rating Details
2/12/2016William BlairReiterated RatingBuyN/AView Rating Details
1/27/2016Janney Montgomery ScottInitiated CoverageBuy$21.00N/AView Rating Details
(Data available from 5/26/2015 forward)

Earnings

Earnings History for Nektar Therapeutics (NASDAQ:NKTR)
Earnings by Quarter for Nektar Therapeutics (NASDAQ:NKTR)
Earnings History by Quarter for Nektar Therapeutics (NASDAQ:NKTR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.40)($0.42)$29.43 million$24.73 millionViewListenView Earnings Details
3/1/2017Q416($0.26)($0.28)$40.83 million$37.45 millionViewListenView Earnings Details
11/3/2016Q316($0.36)($0.32)$32.42 million$36.30 millionViewN/AView Earnings Details
8/3/2016Q216($0.33)($0.36)$34.17 million$32.77 millionViewListenView Earnings Details
5/3/2016Q1($0.23)($0.14)$43.78 million$58.88 millionViewN/AView Earnings Details
3/1/2016Q4($0.42)($0.40)$28.82 million$39.40 millionViewListenView Earnings Details
11/5/2015Q315($0.30)($0.06)$44.30 million$60.00 millionViewN/AView Earnings Details
8/5/2015Q215($0.40)($0.40)$21.49 million$22.66 millionViewN/AView Earnings Details
4/30/2015Q115($0.40)$0.25$20.20 million$108.80 millionViewN/AView Earnings Details
2/24/2015Q414($0.36)($0.35)$12.30 million$19.55 millionViewN/AView Earnings Details
11/6/2014Q314$0.39$0.53$123.20 million$132.90 millionViewN/AView Earnings Details
7/31/2014Q214($0.38)($0.26)$19.76 million$28.50 millionViewListenView Earnings Details
5/7/2014Q114($0.35)($0.37)$38.68 million$19.80 millionViewListenView Earnings Details
2/26/2014Q413($0.17)($0.41)$49.26 million$31.15 millionViewN/AView Earnings Details
11/7/2013Q313($0.22)($0.14)$54.34 million$60.91 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.44)($0.37)$26.22 million$33.86 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.42)($0.48)$26.30 million$23.00 millionViewN/AView Earnings Details
11/9/2012Q312($0.39)($0.38)$21.02 million$18.41 millionViewN/AView Earnings Details
8/9/2012($0.33)($0.30)ViewN/AView Earnings Details
5/2/2012($0.33)($0.36)ViewN/AView Earnings Details
2/29/2012($0.47)($0.33)ViewN/AView Earnings Details
11/2/2011($0.37)($0.21)ViewN/AView Earnings Details
8/4/2011($0.31)($0.32)ViewN/AView Earnings Details
4/27/2011($0.27)($0.33)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Nektar Therapeutics (NASDAQ:NKTR)
2017 EPS Consensus Estimate: ($1.19)
2018 EPS Consensus Estimate: ($1.09)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.49)($0.31)($0.40)
Q2 20172($0.37)($0.29)($0.33)
Q3 20172($0.35)($0.29)($0.32)
Q4 20173($0.33)$0.08($0.14)
Q1 20182($0.35)($0.12)($0.24)
Q2 20182($0.36)($0.13)($0.25)
Q3 20182($0.36)($0.13)($0.25)
Q4 20181($0.36)($0.36)($0.36)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Nektar Therapeutics (NASDAQ:NKTR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Nektar Therapeutics (NASDAQ:NKTR)
Insider Ownership Percentage: 6.10%
Institutional Ownership Percentage: 86.80%
Insider Trades by Quarter for Nektar Therapeutics (NASDAQ:NKTR)
Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)
Insider Trades by Quarter for Nektar Therapeutics (NASDAQ:NKTR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/16/2017Gil M. LabrucherieCFOSell3,179$19.55$62,149.45View SEC Filing  
5/16/2017Howard W RobinCEOSell8,388$19.55$163,985.40View SEC Filing  
5/16/2017John NicholsonCOOSell3,146$19.55$61,504.30View SEC Filing  
5/16/2017Stephen K DobersteinSVPSell1,701$19.55$33,254.55View SEC Filing  
5/15/2017Robert ChessDirectorSell5,000$19.79$98,950.00View SEC Filing  
4/17/2017Robert ChessDirectorSell5,000$18.72$93,600.00View SEC Filing  
4/7/2017Lutz LingnauDirectorSell7,000$20.05$140,350.00View SEC Filing  
4/5/2017Christopher A KueblerDirectorSell15,000$21.88$328,200.00View SEC Filing  
4/5/2017Maninder HoraSVPSell180,000$21.70$3,906,000.00View SEC Filing  
3/20/2017Jillian B. ThomsenSVPSell112,500$19.69$2,215,125.00View SEC Filing  
3/3/2017Gil M. LabrucherieCFOSell200,000$15.16$3,032,000.00View SEC Filing  
2/16/2017Gil M. LabrucherieCFOSell2,359$13.14$30,997.26View SEC Filing  
2/16/2017Howard W RobinCEOSell8,636$13.14$113,477.04View SEC Filing  
2/16/2017Ivan P GergelSVPSell1,457$13.14$19,144.98View SEC Filing  
2/16/2017John NicholsonCOOSell3,237$13.14$42,534.18View SEC Filing  
2/8/2017Howard W RobinCEOSell87,500$13.04$1,141,000.00View SEC Filing  
2/3/2017John NicholsonCOOSell75,000$12.39$929,250.00View SEC Filing  
1/17/2017Howard W RobinCEOSell87,500$12.35$1,080,625.00View SEC Filing  
11/17/2016Howard W RobinCEOSell93,458$13.88$1,297,197.04View SEC Filing  
10/24/2016R Scott GreerDirectorBuy15,000$13.50$202,500.00View SEC Filing  
10/4/2016Howard W. RobinCEOSell87,500$17.06$1,492,750.00View SEC Filing  
9/16/2016Christopher A. KueblerDirectorSell7,500$19.13$143,475.00View SEC Filing  
9/15/2016Robert ChessDirectorSell12,000$19.21$230,520.00View SEC Filing  
9/1/2016Howard W. RobinCEOSell87,500$17.83$1,560,125.00View SEC Filing  
8/16/2016Gil M. LabrucherieCFOSell3,305$17.56$58,035.80View SEC Filing  
8/16/2016Howard W. RobinCEOSell11,817$17.56$207,506.52View SEC Filing  
8/16/2016John NicholsonCOOSell3,317$17.56$58,246.52View SEC Filing  
8/16/2016Stephen K. DobersteinSVPSell1,336$17.56$23,460.16View SEC Filing  
8/1/2016Robert ChessDirectorSell5,000$17.26$86,300.00View SEC Filing  
7/11/2016Jillian B ThomsenCAOSell100,000$15.09$1,509,000.00View SEC Filing  
7/1/2016Robert ChessDirectorSell5,000$14.10$70,500.00View SEC Filing  
5/17/2016Gil M LabrucherieSVPSell836$13.58$11,352.88View SEC Filing  
5/17/2016Howard W RobinCEOSell2,170$13.58$29,468.60View SEC Filing  
5/17/2016Jillian B ThomsenCAOSell724$13.58$9,831.92View SEC Filing  
5/17/2016John NicholsonCFOSell856$13.58$11,624.48View SEC Filing  
4/25/2016Lutz LingnauDirectorSell15,000$16.27$244,050.00View SEC Filing  
2/17/2016Howard W. RobinCEOSell2,147$11.92$25,592.24View SEC Filing  
2/17/2016Jillian B. ThomsenCAOSell716$11.92$8,534.72View SEC Filing  
2/17/2016Maninder HoraSVPSell963$11.92$11,478.96View SEC Filing  
2/10/2016Gil M. LabrucherieSVPSell11,666$11.49$134,042.34View SEC Filing  
2/10/2016Howard W. RobinCEOSell66,666$11.49$765,992.34View SEC Filing  
2/10/2016Jillian B. ThomsenCAOSell15,000$11.49$172,350.00View SEC Filing  
1/20/2016Lutz LingnauDirectorSell15,000$14.51$217,650.00View SEC Filing  
1/19/2016Gil M. LabrucherieSVPSell11,667$14.12$164,738.04View SEC Filing  
1/19/2016Howard W. RobinCEOSell66,667$14.12$941,338.04View SEC Filing  
1/19/2016Jillian B. ThomsenCAOSell15,000$14.12$211,800.00View SEC Filing  
12/4/2015Christopher A. KueblerDirectorSell15,000$15.82$237,300.00View SEC Filing  
12/3/2015Gil M. LabrucherieSVPSell45,001$15.87$714,165.87View SEC Filing  
12/3/2015Howard W. RobinCEOSell125,001$15.87$1,983,765.87View SEC Filing  
12/3/2015Jillian B. ThomsenCAOSell15,000$15.87$238,050.00View SEC Filing  
11/20/2015Susan WangDirectorSell85,000$15.02$1,276,700.00View SEC Filing  
11/11/2015Gil M. LabrucherieSVPSell45,000$13.52$608,400.00View SEC Filing  
11/11/2015Howard W. RobinCEOSell125,000$13.52$1,690,000.00View SEC Filing  
11/11/2015Jillian B. ThomsenCAOSell15,000$13.52$202,800.00View SEC Filing  
10/28/2015Lutz LingnauDirectorSell12,500$12.00$150,000.00View SEC Filing  
10/6/2015Gil M. LabrucherieSVPSell45,000$10.99$494,550.00View SEC Filing  
10/6/2015Howard W. RobinCEOSell125,000$10.99$1,373,750.00View SEC Filing  
10/6/2015Jillian B. ThomsenCAOSell15,000$10.99$164,850.00View SEC Filing  
9/23/2015Gil M. LabrucherieSVPSell44,999$13.04$586,786.96View SEC Filing  
9/23/2015Howard W. RobinCEOSell124,999$13.04$1,629,986.96View SEC Filing  
9/23/2015Jillian B. ThomsenCAOSell10,000$13.04$130,400.00View SEC Filing  
8/13/2015Gil M LabrucherieSVPSell33,333$10.89$362,996.37View SEC Filing  
8/13/2015Howard W RobinCEOSell58,333$10.89$635,246.37View SEC Filing  
7/14/2015Gil M LabrucherieSVPSell33,334$11.78$392,674.52View SEC Filing  
7/14/2015Howard W RobinCEOSell58,334$11.78$687,174.52View SEC Filing  
6/29/2015Susan WangDirectorSell30,000$12.70$381,000.00View SEC Filing  
6/19/2015Robert ChessDirectorSell15,000$11.81$177,150.00View SEC Filing  
6/15/2015Lutz LingnauDirectorSell25,000$11.15$278,750.00View SEC Filing  
12/29/2014Robert ChessDirectorSell29,500$15.34$452,530.00View SEC Filing  
12/22/2014Jillian B ThomsenCAOSell5,000$15.56$77,800.00View SEC Filing  
12/1/2014Gil M LabrucherieSVPSell120,000$17.02$2,042,400.00View SEC Filing  
12/1/2014Howard W RobinCEOSell350,000$17.01$5,953,500.00View SEC Filing  
11/25/2014Howard W RobinCEOSell600,000$15.25$9,150,000.00View SEC Filing  
11/24/2014Gil M LabrucherieSVPSell10,500$15.04$157,920.00View SEC Filing  
11/24/2014Howard W RobinCEOSell132,800$15.02$1,994,656.00View SEC Filing  
11/24/2014Lutz LingnauDirectorSell15,000$15.02$225,300.00View SEC Filing  
11/3/2014Gil M LabrucherieSVPSell9,900$13.78$136,422.00View SEC Filing  
8/5/2013Roy WhitfieldDirectorSell12,500$12.41$155,125.00View SEC Filing  
9/14/2012Dennis L WingerDirectorBuy5,000$9.18$45,900.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Nektar Therapeutics (NASDAQ:NKTR)
Latest Headlines for Nektar Therapeutics (NASDAQ:NKTR)
Source:
DateHeadline
americanbankingnews.com logoRoth Capital Analysts Give Nektar Therapeutics (NKTR) a $31.00 Price Target
www.americanbankingnews.com - May 23 at 9:20 PM
seekingalpha.com logoNektar Therapeutics (NKTR) Presents At UBS Global Healthcare Conference 2017 - Slideshow
seekingalpha.com - May 23 at 6:20 PM
seekingalpha.com logoNektar and Takeda team up to explore anti-cancer potential of NKTR-214
seekingalpha.com - May 22 at 6:05 PM
finance.yahoo.com logoNew Research Collaboration between Nektar and Takeda to Explore Combination Cancer Therapy Approaches with NKTR-214, a CD122-Biased Agonist, and Five Takeda Cancer Therapy Compounds
finance.yahoo.com - May 22 at 9:55 AM
americanbankingnews.com logoNektar Therapeutics (NKTR) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - May 22 at 7:58 AM
prnewswire.com logoNektar Therapeutics Announces Data Presentations at ASCO 2017 - PR Newswire (press release)
www.prnewswire.com - May 20 at 11:30 PM
finance.yahoo.com logoNektar Therapeutics breached its 50 day moving average in a Bearish Manner : NKTR-US : May 18, 2017
finance.yahoo.com - May 19 at 11:38 AM
americanbankingnews.com logoNektar Therapeutics (NKTR) SVP Stephen K. Doberstein Sells 1,701 Shares
www.americanbankingnews.com - May 18 at 10:23 PM
americanbankingnews.com logoNektar Therapeutics (NKTR) CEO Sells $163,985.40 in Stock
www.americanbankingnews.com - May 18 at 10:22 PM
americanbankingnews.com logoInsider Selling: Nektar Therapeutics (NKTR) COO Sells 3,146 Shares of Stock
www.americanbankingnews.com - May 18 at 10:22 PM
americanbankingnews.com logoGil M. Labrucherie Sells 3,179 Shares of Nektar Therapeutics (NKTR) Stock
www.americanbankingnews.com - May 18 at 10:22 PM
finance.yahoo.com logoNektar Therapeutics Announces Data Presentations at ASCO 2017
finance.yahoo.com - May 18 at 8:08 AM
americanbankingnews.com logoNektar Therapeutics (NKTR) Director Robert Chess Sells 5,000 Shares
www.americanbankingnews.com - May 17 at 8:10 PM
finance.yahoo.com logoNektar to Webcast Presentation at UBS Global Healthcare Conference 2017 in New York
finance.yahoo.com - May 15 at 6:11 PM
finance.yahoo.com logoETFs with exposure to Nektar Therapeutics : May 15, 2017
finance.yahoo.com - May 15 at 6:11 PM
americanbankingnews.com logoNektar Therapeutics (NKTR) Rating Reiterated by Aegis
www.americanbankingnews.com - May 14 at 4:34 PM
americanbankingnews.com logoNektar Therapeutics (NKTR) Given a $31.00 Price Target at Roth Capital
www.americanbankingnews.com - May 13 at 6:58 PM
seekingalpha.com logoNektar Therapeutics' (NKTR) CEO Howard Robin On Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 13 at 8:31 AM
finance.yahoo.com logoNektar Therapeutics :NKTR-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
finance.yahoo.com - May 12 at 7:29 PM
americanbankingnews.com logoNektar Therapeutics (NKTR) to Post Q2 2017 Earnings of ($0.37) Per Share, William Blair Forecasts
www.americanbankingnews.com - May 12 at 9:21 AM
americanbankingnews.com logoJefferies Group Comments on Nektar Therapeutics' Q2 2017 Earnings (NKTR)
www.americanbankingnews.com - May 12 at 9:20 AM
americanbankingnews.com logoNektar Therapeutics (NKTR) to Post Q4 2017 Earnings of $0.08 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - May 11 at 12:26 PM
americanbankingnews.com logo$56.92 Million in Sales Expected for Nektar Therapeutics (NKTR) This Quarter
www.americanbankingnews.com - May 11 at 11:00 AM
zacks.com logoNektar Therapeutics (NKTR) Loss Wider Than Expected in Q1
www.zacks.com - May 11 at 9:23 AM
americanbankingnews.com logoNektar Therapeutics (NKTR) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 10 at 8:28 PM
americanbankingnews.com logoNektar Therapeutics' (NKTR) Buy Rating Reaffirmed at Jefferies Group LLC
www.americanbankingnews.com - May 10 at 8:20 PM
rttnews.com logoEARNINGS SUMMARY: Details of Nektar Therapeutics Q1 Earnings Report
www.rttnews.com - May 10 at 7:02 PM
finance.yahoo.com logoThe Not-So-Subtle Reason Behind Nektar Therapeutics' 10% Pop
finance.yahoo.com - May 10 at 7:02 PM
fool.com logoThe Not-So-Subtle Reason Behind Nektar Therapeutics' 10% Pop
www.fool.com - May 10 at 5:56 PM
finance.yahoo.com logoEdited Transcript of NKTR earnings conference call or presentation 9-May-17 9:00pm GMT
finance.yahoo.com - May 10 at 12:05 PM
seekingalpha.com logoShowtime For Nektar Therapeutics - Seeking Alpha
seekingalpha.com - May 9 at 6:28 PM
finance.yahoo.com logoInvestor Network: Nektar Therapeutics to Host Earnings Call
finance.yahoo.com - May 9 at 6:28 PM
finance.yahoo.com logoNektar Therapeutics Reports Financial Results for the First Quarter of 2017
finance.yahoo.com - May 9 at 6:28 PM
finance.yahoo.com logoNektar reports 1Q loss
finance.yahoo.com - May 9 at 6:28 PM
americanbankingnews.com logoZacks: Analysts Expect Nektar Therapeutics (NKTR) Will Announce Earnings of -$0.40 Per Share
www.americanbankingnews.com - May 9 at 4:32 PM
finance.yahoo.com logoNektar Therapeutics – Value Analysis (NASDAQ:NKTR) : May 8, 2017
finance.yahoo.com - May 8 at 6:19 PM
finance.yahoo.com logoWhy Nektar Therapeutics Shares Fell 19.2% in April
finance.yahoo.com - May 6 at 8:50 AM
finance.yahoo.com logoNektar Therapeutics breached its 50 day moving average in a Bullish Manner : NKTR-US : May 5, 2017
finance.yahoo.com - May 5 at 9:16 AM
americanbankingnews.com logoNektar Therapeutics (NKTR) Given Daily News Sentiment Score of 0.19
www.americanbankingnews.com - May 3 at 9:38 PM
prnewswire.com logoNektar Appoints Brian L. Kotzin, M.D. as Head of Clinical Development for Nektar's Immunology Program - PR Newswire (press release)
www.prnewswire.com - May 3 at 5:51 PM
finance.yahoo.com logoNektar Appoints Brian L. Kotzin, M.D. as Head of Clinical Development for Nektar's Immunology Program
finance.yahoo.com - May 3 at 5:51 PM
finance.yahoo.com logoNektar to Announce Financial Results for the First Quarter of 2017 on Tuesday, May 9, 2017, After Close of U.S.-Based Financial Markets
finance.yahoo.com - May 2 at 7:51 PM
seekingalpha.com logoMannKind: Mann Trust Executors Are Selling Massive Numbers Of Common Shares
seekingalpha.com - May 1 at 5:47 PM
americanbankingnews.com logoSomewhat Positive Press Coverage Very Likely to Impact Nektar Therapeutics (NKTR) Share Price
www.americanbankingnews.com - April 30 at 6:05 PM
americanbankingnews.com logoNektar Therapeutics (NKTR) Set to Announce Earnings on Monday
www.americanbankingnews.com - April 29 at 10:34 AM
americanbankingnews.com logoNektar Therapeutics (NKTR) Given Daily News Sentiment Score of 0.11
www.americanbankingnews.com - April 27 at 8:32 PM
streetinsider.com logoNektar Therapeutics (NKTR): Notes From The Road - Jefferies
www.streetinsider.com - April 25 at 6:05 PM
americanbankingnews.com logoNektar Therapeutics (NKTR) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - April 25 at 1:17 PM
americanbankingnews.com logoSomewhat Positive News Coverage Likely to Affect Nektar Therapeutics (NKTR) Stock Price
www.americanbankingnews.com - April 24 at 9:14 PM
streetinsider.com logoNektar Therapeutics (NKTR): Notes From The Road - Jefferies - StreetInsider.com
www.streetinsider.com - April 24 at 3:07 PM

Social

Chart

Nektar Therapeutics (NKTR) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by MarketBeat.com Staff